Multiple Myeloma International Staging System (ISS)
ورودیهای بالینی بیمار
حداقل ۰.۱ — حداکثر ۵۰ • واحد: mg/L
حداقل ۱ — حداکثر ۶ • واحد: g/dL
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Stage I1–1
- Stage II2–2
- Stage III3–3
The Multiple Myeloma International Staging System (ISS) calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include serum beta2 microglobulin. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Prognosticates severity of multiple myeloma based on routinely obtained lab values including serum β2 microglobulin and albumin levels.
Clinical Indication
The Multiple Myeloma International Staging System (ISS) is indicated for bedside clinical practice to support Prognosticates severity of multiple myeloma based on routinely obtained lab values including serum β2 microglobulin and albumin levels.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Results help guide treatment intensity and prognosis counseling.
ISS Stage determination: Stage I = β2 microglobulin <3.5 mg/L AND albumin ≥3.5 g/dL; Stage II = (β2 microglobulin <3.5 mg/L AND albumin <3.5 g/dL) OR (β2 microglobulin 3.5-5.4 mg/L); Stage III = β2 microglobulin ≥5.5 mg/L
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| serum_beta2_microglobulin | float | Yes | Serum β2 microglobulin level(mg/L) |
| serum_albumin | float | Yes | Serum albumin level(g/dL) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 1–1 | Stage I | Best prognosis |
| 2–2 | Stage II | Intermediate prognosis |
| 3–3 | Stage III | Poorest prognosis |
Evidence-Based References (EBM)
- Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412-20. doi: 10.1200/JCO.2005.04.242.DOI: 10.1200/JCO.2005.04.242
- Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842-54. doi: 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u.DOI: 10.1002/1097-0142(197509)36:3
- Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267.DOI: 10.1200/JCO.2015.61.2267